EP0806204A1 - Produktions inhibitor von inflammatorischen zytokinen enthaltend ein polyprenylderivat als wirkstoff - Google Patents
Produktions inhibitor von inflammatorischen zytokinen enthaltend ein polyprenylderivat als wirkstoff Download PDFInfo
- Publication number
- EP0806204A1 EP0806204A1 EP95900931A EP95900931A EP0806204A1 EP 0806204 A1 EP0806204 A1 EP 0806204A1 EP 95900931 A EP95900931 A EP 95900931A EP 95900931 A EP95900931 A EP 95900931A EP 0806204 A1 EP0806204 A1 EP 0806204A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- active ingredient
- hydrogen atom
- therapy
- prophylaxis
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000004480 active ingredient Substances 0.000 title claims abstract description 53
- 230000002757 inflammatory effect Effects 0.000 title claims abstract description 35
- 239000003112 inhibitor Substances 0.000 title claims abstract description 12
- 125000001185 polyprenyl group Polymers 0.000 title claims description 55
- 230000016396 cytokine production Effects 0.000 title abstract 4
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims abstract description 45
- 125000002252 acyl group Chemical group 0.000 claims abstract description 28
- 208000009137 Behcet syndrome Diseases 0.000 claims abstract description 21
- 208000011231 Crohn disease Diseases 0.000 claims abstract description 14
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims abstract description 11
- 238000002560 therapeutic procedure Methods 0.000 claims description 39
- 108090000695 Cytokines Proteins 0.000 claims description 36
- 102000004127 Cytokines Human genes 0.000 claims description 36
- 238000011321 prophylaxis Methods 0.000 claims description 36
- 230000015572 biosynthetic process Effects 0.000 claims description 34
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 29
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 29
- 238000000034 method Methods 0.000 claims description 28
- 239000003795 chemical substances by application Substances 0.000 claims description 26
- 208000027496 Behcet disease Diseases 0.000 claims description 19
- -1 cinnamoyl group Chemical group 0.000 claims description 19
- 201000010099 disease Diseases 0.000 claims description 19
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 19
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 17
- 125000001931 aliphatic group Chemical group 0.000 claims description 15
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 14
- 125000003118 aryl group Chemical group 0.000 claims description 11
- 230000005764 inhibitory process Effects 0.000 claims description 10
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 9
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims description 6
- 230000000694 effects Effects 0.000 abstract description 16
- 230000002401 inhibitory effect Effects 0.000 abstract description 13
- 230000003449 preventive effect Effects 0.000 abstract description 5
- 208000028774 intestinal disease Diseases 0.000 abstract 2
- 206010009887 colitis Diseases 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 229920006389 polyphenyl polymer Polymers 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 description 40
- UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 description 18
- NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical class C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 description 18
- 229960001940 sulfasalazine Drugs 0.000 description 18
- NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 description 18
- 208000027503 bloody stool Diseases 0.000 description 14
- 208000035861 hematochezia Diseases 0.000 description 14
- 206010012735 Diarrhoea Diseases 0.000 description 12
- 230000001225 therapeutic effect Effects 0.000 description 12
- 208000024891 symptom Diseases 0.000 description 10
- 206010000087 Abdominal pain upper Diseases 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 7
- 208000003265 stomatitis Diseases 0.000 description 7
- 230000007012 clinical effect Effects 0.000 description 6
- VQAWRQZAAIQXHM-UHFFFAOYSA-N Cepharanthine Natural products O1C(C=C2)=CC=C2CC(C=23)N(C)CCC3=CC=3OCOC=3C=2OC(=CC=23)C(OC)=CC=2CCN(C)C3CC2=CC=C(O)C1=C2 VQAWRQZAAIQXHM-UHFFFAOYSA-N 0.000 description 5
- 102000004890 Interleukin-8 Human genes 0.000 description 5
- 108090001007 Interleukin-8 Proteins 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- YVPXVXANRNDGTA-WDYNHAJCSA-N cepharanthine Chemical compound C1C(C=C2)=CC=C2OC(=C2)C(OC)=CC=C2C[C@H](C2=C3)N(C)CCC2=CC(OC)=C3OC2=C(OCO3)C3=CC3=C2[C@H]1N(C)CC3 YVPXVXANRNDGTA-WDYNHAJCSA-N 0.000 description 5
- 210000005259 peripheral blood Anatomy 0.000 description 5
- 239000011886 peripheral blood Substances 0.000 description 5
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 5
- 229960005205 prednisolone Drugs 0.000 description 5
- 125000001424 substituent group Chemical group 0.000 description 5
- 206010016717 Fistula Diseases 0.000 description 4
- 108090001005 Interleukin-6 Proteins 0.000 description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 4
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000003890 fistula Effects 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 102100032752 C-reactive protein Human genes 0.000 description 3
- 206010028140 Mucous stools Diseases 0.000 description 3
- 208000025865 Ulcer Diseases 0.000 description 3
- 229960000772 camostat Drugs 0.000 description 3
- XASIMHXSUQUHLV-UHFFFAOYSA-N camostat Chemical compound C1=CC(CC(=O)OCC(=O)N(C)C)=CC=C1OC(=O)C1=CC=C(N=C(N)N)C=C1 XASIMHXSUQUHLV-UHFFFAOYSA-N 0.000 description 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000036269 ulceration Effects 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical compound BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 231100000053 low toxicity Toxicity 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 2
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 108010074051 C-Reactive Protein Proteins 0.000 description 1
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 206010015226 Erythema nodosum Diseases 0.000 description 1
- 206010061149 Female genital tract fistula Diseases 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- 206010018693 Granuloma inguinale Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000006193 Pulmonary infarction Diseases 0.000 description 1
- 208000003776 Rectovaginal Fistula Diseases 0.000 description 1
- 125000003647 acryloyl group Chemical group O=C([*])C([H])=C([H])[H] 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 125000003074 decanoyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C(*)=O 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 208000027993 eye symptom Diseases 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 125000000268 heptanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 206010022694 intestinal perforation Diseases 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000000400 lauroyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229920006008 lipopolysaccharide Polymers 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- XMSZANIMCDLNKA-UHFFFAOYSA-N methyl hypofluorite Chemical compound COF XMSZANIMCDLNKA-UHFFFAOYSA-N 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 230000002956 necrotizing effect Effects 0.000 description 1
- 125000001402 nonanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002801 octanoyl group Chemical group C(CCCCCCC)(=O)* 0.000 description 1
- 206010034674 peritonitis Diseases 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- SUWYPNNPLSRNPS-UNTSEYQFSA-N plaunotol Chemical compound CC(C)=CCC\C(C)=C\CC\C(CO)=C\CC\C(C)=C\CO SUWYPNNPLSRNPS-UNTSEYQFSA-N 0.000 description 1
- 229950009291 plaunotol Drugs 0.000 description 1
- SUWYPNNPLSRNPS-UHFFFAOYSA-N plaunotol Natural products CC(C)=CCCC(C)=CCCC(CO)=CCCC(C)=CCO SUWYPNNPLSRNPS-UHFFFAOYSA-N 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000007575 pulmonary infarction Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000010410 reperfusion Effects 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000009495 sugar coating Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 125000003774 valeryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/08—Ethers or acetals acyclic, e.g. paraformaldehyde
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
Definitions
- the present invention concerns an inhibitor of inflammatory cytokine formation comprising polyprenyl derivatives as the active ingredient, and a method for the prophylaxis and/or treatment of diseases, which method is based on the inhibition of inflammatory cytokine formation by use of polyprenyl derivatives as the active ingredient.
- Inflammatory bowel diseases include ulcerative colitis and Crohn's disease. In both of these diseases, intractable ulceration or inflammation occurs in the intestinal tract of a young adult, and each is designated as one of the intractable diseases in this country.
- Inflammatory bowel diseases occur frequently in the developed countries in Europe and America, and their sudden increase has also been observed in this country. A therapeutic method for these diseases has not yet been established, with the lone exception of a finding that sulfasalazine or a steroid derivative such as prednisolone is partly effective.
- Behcet syndrome is a disease showing four main symptoms, stomatitis, skin symptoms, pudendal ulcer and eye symptoms.
- a disease showing the above four symptoms and having additional intestinal symptoms is known as intestinal type Behcet syndrome. These four main symptoms are convenient for diagnosis. However, these do not directly cause direct death, the main cause of death from Behcet syndrome being peritonitis caused by intestinal perforation.
- TNF ⁇ tumor necrotizing factor- ⁇
- IL-6 interleukine-6
- IL-8 interleukine-8
- the present inventors studied the pharmacological activities of various polyprenyl derivatives for many years. Their study resulted in the discovery that certain polyprenyl derivatives have an excellent activity in inhibiting the formation of inflammatory cytokines and they exhibit an excellent therapeutic effect on inflammatory bowel diseases including ulcerative colitis and Crohn's disease and on Behcet syndrome, and they have low toxicity; and that these derivatives are useful as an agent for inhibiting inflammatory cytokine formation and as a therapeutic and preventive agent for inflammatory bowel diseases and Behcet syndrome; and this resulted in completion of the present invention.
- the polyprenyl derivatives of the present invention are known to have antiulcer activity (for example, Japanese Patent Application Kokai No. Sho 52-62213 etc.,), their activity in inhibiting the formation of inflammatory cytokines, their therapeutic effect on inflammatory bowel diseases etc., are not known.
- polyprenyl derivatives the active ingredient of the present invention, have the general formula:
- the C 1 -C 4 alkyl group may be, for example, a methyl, ethyl, propyl, isopropyl, butyl, sec-butyl or isobutyl group; preferably a C 1 -C 2 alkyl group; and particularly preferably a methyl group.
- the C 2 -C 12 aliphatic acyl group may have double bond(s) and may be an acetyl, propionyl, butyryl, valeryl, isovaleryl, caproyl, heptanoyl, octanoyl, nonanoyl, decanoyl, lauroyl, acryloyl, metacryloyl, crotonoyl or 3-butenoyl group; preferably a C 2 -C 6 aliphatic acyl group and particularly preferably an acetyl group.
- the C 7 -C 11 aromatic acyl group may be, for example, a benzoyl or naphtoyl group; preferably a benzoyl group.
- the aromatic acyl group may have substituent(s) on the ring; and the substituent may be the aforementioned C 1 -C 4 alkyl group; a C 1 -C 4 alkoxy group such as a methoxy, ethoxy, propoxy, isopropoxy or butoxy group; or a halogen atom such as a fluorine, chlorine, bromine or iodine atom; preferably a methyl, methoxy, fluorine or chlorine atom.
- the C 8 -C 12 aryl-substituted aliphatic acyl group may have double bond, and may be a phenylacetyl, phenylpropionyl, phenylbutyryl, phenylvaleryl, naphthylacetyl or cinnamoyl group; preferably a phenylacetyl or cinnamoyl group; and particularly preferably a cinnamoyl group.
- the aryl-substituted aliphatic acyl group may have substituent(s) on the ring; and the substituents may be the same substituents as mentioned already for the aromatic acyl group.
- a compound in which the groups are combined with ones selected optionally from the groups (1) to (5) may be also preferable.
- Preferred compounds represented by the general formula (I) may be exemplified concretely in the following Table 1.
- polyprenyl derivatives having the general formula (I), which are the active ingredient of the present invention are known compounds, or can be prepared easily according to the known methods (for example, Japanese Patent Application Kokai No. Sho 52-62213 etc.).
- the polyprenyl derivatives of the present invention have an excellent activity in inhibiting the formation of inflammatory cytokines, they exhibit an excellent therapeutic effect on inflammatory bowel diseases and Behcet syndrome, and they show low toxicity. Therefore these derivatives are useful as a therapeutic and preventive agent for various kinds of diseases mentioned below, based on their inhibiting effect on the formation of inflammatory cytokines etc.
- polyprenyl derivatives having the general formula (I), which are the active ingredient of the present invention are preferably useful as a therapeutic and prophylatic agent for inflammatory bowel diseases or for Behcet syndrome, more preferably as a therapeutic and preventive agent for inflammatory bowel diseases, and particularly preferably as a therapeutic and preventive agent for ulcerative colitis and Crohn's disease.
- polyprenyl derivatives having the general formula (I), which are the active ingredient of the present invention have an excellent activity in inhibiting the formation of inflammatory cytokines, they exhibit an excellent therapeutic effect on inflammatory bowel diseases and Behcet syndrome, and they are useful as a therapeutic and prophylactic agent for inflammatory bowel diseases.
- the derivatives having the general formula (I), which are the active ingredient of the present invention are used as an agent for inhibiting inflammatory cytokine formation
- the derivatives by themselves or a mixture of the derivatives and any pharmaceutically acceptable carriers, vehicles, diluents etc. may be administered orally or parenterally (including intrarectal administration) as pharmaceutical compositions such as powders, granules, tablets, capsules, injections, suppositories etc., and preferably orally.
- a dose of from 1 mg to 1000 mg (preferably from 10 mg to 500 mg) in a case of oral administration, and a dose of from 0.1 mg to 500 mg (preferably from 1 mg to 300 mg) in the case of intravenous administration, may be given one to three times a day according to the symptoms.
- a peripheral blood sample (to which heparin was added) was taken from each of 3 patients with ulcerative colitis during active stage and 3 patients with Crohn's disease. The samples were separated by their specific gravity using Ficoll-Lonray Percoll to give monocyte (Mo) and macrophage (M ⁇ ) fractions. 10% fetal cow serum (FCS) was added to these fractions and the mixture was prepared to be 1 x 10 4 cells/ml, by use of Rosewell Park Memorial Institute medium (RPMI-1640).
- FCS fetal cow serum
- Compound No. 12 has a significant inhibitory effect, at a concentration of 10 -6 M, on the formation of three kinds of cytokines, TNF ⁇ , IL-6 and IL-8, in the Mo-M ⁇ cell systems derived from peripheral blood samples of patients with ulcerative colitis and Crohn's disease (a decreased effect was observed on the levels of IL-8 in the peripheral blood Mo-M ⁇ cell system derived from patients with ulcerative colitis); and it shows equivalent or greater utility compared to sulfasalazine or prednisolone.
- Compound No. 12 was administered to 5 patients with ulcerative colitis (active stage) at a daily dosage of from 3 tablets (240 mg) to 6 tablets (480 mg) divided into 3 doses.
- the patients were 3 females and 2 males from 21 to 46 years old.
- 4 cases had not shown improvement even after administration of 6 tablets (3.0 g) a day of sulfasalazine for 3 months, and the other case was incipient.
- the results are shown in Table 4.
- Table 4 Clinical effect of Compound No. 12 in patients with ulcerative colitis Case (Age) Dosage & Adm. period Clinical symptom Clinical judgement Effect of combined drug 3 months before Adm. Before Adm. After Adm. 1.
- Compound No. 12 was administered to 3 patients with Crohn's disease (active stage) at a daily dosage of 6 tablets (480 mg) divided into 3 doses.
- the patients were 1 female and 2 males from 28 to 44 years old.
- 2 cases had not been improved even after administration of 6 tablets (3.0 g) a day of sulfasalazine for 3 months, and 1 case had not been improved even after combined administration of 6 tablets (3.0 g) a day of sulfasalazine, 6 tablets (3.0 g) a day of camostat mesilate and 6 tablets (3.0 g) a day of cepharanthine for 3 months.
- Table 5 Clinical effect of Compound No.
- this compound may be effective for the therapy of fistula such as internal fistula or outer fistula.
- Compound No. 12 was administered to a patient with Behcet syndrome (active stage) at a daily dosage of 6 tablets (480 mg) divided into 3 doses.
- the patient was a 51 years old female with the main three symptoms of Behcet syndrome, pudendal ulceration, recurrent stomatitis and erythema nodosum of the legs, accompanied by multiple apthous ulceration throughout the intestinal tract.
- Table 6 Clinical effect of Compound No.
- a powder containing the above components is mixed, filtered through a sieve of 60 mesh and then incorporated in a No. 2 gelatine capsule for 250 mg to obtain the desired capsule preparation.
- a powder containing the above components is mixed and tableted by use of a tableting machine to obtain the aimed 250 mg tablet preparation.
- this tablet can be covered with a sugar coating.
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP30075193 | 1993-12-01 | ||
| JP300751/93 | 1993-12-01 | ||
| PCT/JP1994/001971 WO1995015159A1 (en) | 1993-12-01 | 1994-11-22 | Inflammatory cytokine production inhibitor containing polyprenyl derivative as active ingredient |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP0806204A1 true EP0806204A1 (de) | 1997-11-12 |
| EP0806204A4 EP0806204A4 (de) | 2001-06-27 |
Family
ID=17888662
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP95900931A Withdrawn EP0806204A4 (de) | 1993-12-01 | 1994-11-22 | Produktions inhibitor von inflammatorischen zytokinen enthaltend ein polyprenylderivat als wirkstoff |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US5708037A (de) |
| EP (1) | EP0806204A4 (de) |
| KR (1) | KR960706333A (de) |
| CN (1) | CN1142765A (de) |
| AU (1) | AU683112B2 (de) |
| CA (1) | CA2177966A1 (de) |
| CZ (1) | CZ282294B6 (de) |
| FI (1) | FI962264A7 (de) |
| HU (1) | HUT74983A (de) |
| NO (1) | NO962212L (de) |
| NZ (1) | NZ276178A (de) |
| RU (1) | RU2141318C1 (de) |
| WO (1) | WO1995015159A1 (de) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0931544A3 (de) * | 1997-12-22 | 2004-08-25 | Kaken Shoyaku Co., Ltd. | Hemmer der NF-kB Aktivität |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1935427B1 (de) * | 2000-07-03 | 2018-03-07 | Bristol-Myers Squibb Company | Verwendung von löslichen mutanten CTLA4-Mutantenmolekülen |
| US20040022787A1 (en) | 2000-07-03 | 2004-02-05 | Robert Cohen | Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID |
| KR100448488B1 (ko) * | 2001-09-03 | 2004-09-13 | (주)프로테옴텍 | 베체트병의 질병 표시인자로서의 아포리포프로테인에이-1을 이용한 진단 시스템 |
| JP4235170B2 (ja) * | 2002-05-17 | 2009-03-11 | ジェン−プロウブ インコーポレイテッド | 離脱可能なロック機構を有するサンプルキャリア |
| RU2251694C2 (ru) * | 2003-04-30 | 2005-05-10 | Российский НИИ геронтологии Минздрава РФ | Способ дифференциальной диагностики язвенного колита и болезни крона |
| MD480Z5 (ro) * | 2011-07-07 | 2012-09-30 | Эльвира АНДОН | Metodă de tratament al colitei ulceroase nespecifice acute |
| CN108358788A (zh) * | 2017-02-04 | 2018-08-03 | 周厚广 | 有机物对映体纯oa及其在制备ⅱ型糖尿病及血管并发症药物中的用途 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4192953A (en) * | 1975-11-18 | 1980-03-11 | Sankyo Company Limited | Polyprenyl derivatives |
| US4059641A (en) * | 1975-11-18 | 1977-11-22 | Sankyo Company Limited | Polyprenyl derivatives |
| JPS57154123A (en) * | 1981-03-17 | 1982-09-22 | Sankyo Co Ltd | Remedial promotor for wound |
| US4927815A (en) * | 1988-04-29 | 1990-05-22 | Wisconsin Alumni Research Foundation | Compounds effective in inducing cell differentiation and process for preparing same |
-
1994
- 1994-11-22 CA CA002177966A patent/CA2177966A1/en not_active Abandoned
- 1994-11-22 NZ NZ276178A patent/NZ276178A/xx unknown
- 1994-11-22 WO PCT/JP1994/001971 patent/WO1995015159A1/ja not_active Ceased
- 1994-11-22 RU RU96115259A patent/RU2141318C1/ru active
- 1994-11-22 CN CN94194936A patent/CN1142765A/zh active Pending
- 1994-11-22 HU HU9601460A patent/HUT74983A/hu unknown
- 1994-11-22 AU AU10346/95A patent/AU683112B2/en not_active Ceased
- 1994-11-22 CZ CZ961566A patent/CZ282294B6/cs not_active IP Right Cessation
- 1994-11-22 EP EP95900931A patent/EP0806204A4/de not_active Withdrawn
- 1994-11-22 KR KR1019960702851A patent/KR960706333A/ko not_active Ceased
-
1996
- 1996-05-30 FI FI962264A patent/FI962264A7/fi unknown
- 1996-05-30 NO NO962212A patent/NO962212L/no not_active Application Discontinuation
- 1996-05-31 US US08/656,576 patent/US5708037A/en not_active Expired - Fee Related
Non-Patent Citations (2)
| Title |
|---|
| See also references of WO9515159A1 * |
| VILELA M P ET AL: "ÄUse of geranyl farnesylacetate in patients with non-specific ulcerative rectocolitisÜ. O emprego do farnesilacetato de geranila em pacientes com retocolite ulcerativa inespecifica." HOSPITAL, (1967 MAR) 71 (3) 691-6. , XP000995691 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0931544A3 (de) * | 1997-12-22 | 2004-08-25 | Kaken Shoyaku Co., Ltd. | Hemmer der NF-kB Aktivität |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2177966A1 (en) | 1995-06-08 |
| CZ156696A3 (en) | 1997-01-15 |
| NO962212D0 (no) | 1996-05-30 |
| HUT74983A (en) | 1997-03-28 |
| FI962264A7 (fi) | 1996-07-05 |
| CN1142765A (zh) | 1997-02-12 |
| AU683112B2 (en) | 1997-10-30 |
| WO1995015159A1 (en) | 1995-06-08 |
| US5708037A (en) | 1998-01-13 |
| RU2141318C1 (ru) | 1999-11-20 |
| NZ276178A (en) | 1997-08-22 |
| KR960706333A (ko) | 1996-12-09 |
| FI962264A0 (fi) | 1996-05-30 |
| CZ282294B6 (cs) | 1997-06-11 |
| NO962212L (no) | 1996-07-31 |
| AU1034695A (en) | 1995-06-19 |
| EP0806204A4 (de) | 2001-06-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0049119B1 (de) | Cephalosporinverbindungen, Verfahren zu ihrer Herstellung und sie enthaltende pharmazeutische Präparate | |
| EP0395441A2 (de) | Behandlungsmittel gegen Osteoarthritis | |
| US5708037A (en) | Inhibitor of inflammatory cytokine formation comprising polyprenyl derivatives as the active ingredient | |
| EP0270690B1 (de) | Arzneimittel zur behandlung und prophylaxe von leber- und nierenkrankheiten | |
| EP0292660B1 (de) | Alkylidendithiobis (substituierte) Phenolen zur Hemmung der Freisetzung von Interleukin-1 und zur Linderung von Interleukin-1 vermittelten Krankheiten | |
| EP0399051B1 (de) | Polyvalentes entzündungshemmendes mittel | |
| EP0137832B1 (de) | Arzneimittelzusammensetzungen mit anti-entzündungswirkung auf die bauchspeicheldrüse | |
| EP0273375A2 (de) | Propiophenonderivate zur Behandlung der Pollakiurie (Drang zu häufiger Harnentleerung) | |
| HK1003050A (en) | Inflammatory cytokine production inhibitor containing polyprenyl derivative as active ingredient | |
| CA2289880C (en) | A therapeutic agent for intractable vasculitis | |
| JP2000239293A (ja) | マルトオリゴ糖誘導体及びその用途 | |
| KR0185226B1 (ko) | 이식 조직의 거부반응 억제제 및 il-1 생산 억제제 | |
| CA2065798A1 (en) | Use of 2-iminothiazolidin-4-one derivatives as novel pharmaceutical active ingredients | |
| EP0410305A2 (de) | Verwendung von Bis(4-hydroxyphenylthio)methan-Derivaten zur Behandlung von Diabetes mellitus | |
| JPH07206667A (ja) | ポリプレニル誘導体を有効成分とする炎症性サイトカイン産生抑制剤 | |
| EP0504807B1 (de) | Verwendung von Bis-(p-Hydroxyphenylthio)methanderivaten zur Hemmung der fortschreitenden Entwicklung von insulinabhängingem Diabetes mellitus | |
| EP0697215A1 (de) | Mittel gegen verdauungsbeschwerden | |
| EP0410343A2 (de) | Verwendung von bisphenol-Derivaten zur Behandlung von Diabetes mellitus | |
| EP0653209A1 (de) | Arzneimittel für entzündliche darmerkrankungen | |
| US3910960A (en) | Gulonic acid salt | |
| US4073910A (en) | Method for treatment of diabetes | |
| EP0521381A1 (de) | Verwendung von 3-Pyridazinone zur Verringerung der Blutplätchenzahl | |
| US3714362A (en) | Acetic acid derivatives as hypolipidemics | |
| JPH06116143A (ja) | 抗高脂血症剤及び抗動脈硬化症剤 | |
| CN120271654A (zh) | 一种白桦脂酸型皂苷衍生物及制备方法与应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 19960607 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE |
|
| A4 | Supplementary search report drawn up and despatched |
Effective date: 20010514 |
|
| AK | Designated contracting states |
Kind code of ref document: A4 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
| 18D | Application deemed to be withdrawn |
Effective date: 20011113 |
|
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1003050 Country of ref document: HK |